This project's long-term goal is the development and clinical validation of a useful diagnostic blood test for the disease sarcoidosis. Sarcoidosis is an inflammatory disorder characterized by granulomas, most commonly in the lungs. Its cause is unknown. The diagnosis of sarcoidosis is currently one of exclusion;there is no reliable, affirmative, rule-in, diagnostic test. Namely, the patient
100 already identified) candidate peptide phage, to determine their sensitivity and specificity in the diagnosis of sarcoidosis. Our Preliminary Data shows that these peptides are immunoreactive with at least some sarcoidosis sera, and not with normal control sera or sera from PPD+ individuals. We will analyze the immunoreactivity of each peptide with at least 58 sarcoidosis sera and >110 control sera. The sera are provided through a consortium of clinical collaborators at Tufts Medical Center, Boston University Medical Center, and Vanderbilt University Medical Center. In Aim 2, we will combine the best- performing peptides into a single immunoassay, for superior sensitivity. In addition to sensitivity and specificity, we will also evaluate precision, linearity, and assay stability. In a future Phase II, we will conduct a prospective study, with an independent set of patients, for regulatory submission.
Public Health Relevance:
This project is for the purpose of creating a blood test for sarcoidosis, a disease of unknown cause and for which there is no definitive test. The new technology that we employed to discover the immune response targets for this test is applicable to many other diseases involving the body
Thesaurus Terms:
Atgn;Academic Medical Centers;Affect;Antibodies;Antigenic Determinants;Antigens;Applications Grants;Assay;Bacteriophage M13;Bacteriophages;Be Element;Beryllium;Besnier-Boeck Disease;Binding Determinants;Bioassay;Biologic Assays;Biological Assay;Biopsy;Blood;Blood Serum;Blood Tests;Boeck's Sarcoid;Boston;Causality;Chest;City Of Boston;Clinical;Clinical Evaluation;Clinical Testing;Coliphage M13;Collaborations;Data;Development;Diagnosis;Diagnostic;Diagnostic Tests;Disease;Disorder;Drug Formulations;Enterobacteria Phage M13;Environment;Epidemiology, Personal Medical History;Epitopes;Etiology;Exclusion;Exposure To;Eye;Eyeball;Formulation;Formulations, Drug;Fostering;Future;Goals;Grant Proposals;Grants, Applications;Granuloma;Granulomatous;Granulomatous Lesion;Hematologic Tests;Hematological Tests;Hematology Testing;Inflm;Immune Response;Immune System;Immunoassay;Individual;Infectious Agent;Inflammation;Inflammatory;Investigators;Libraries;Lung;M. Tb;M. Tuberculosis;M.Tb;M.Tuberculosis;M13 Phage;Measurement;Measures;Mediating;Medical History;Medical Center;Methods;Methods And Techniques;Methods, Other;Mycobacterium Tuberculosis;Pathologic;Patients;Peptide Library;Peptides;Personal Medical History;Phages;Phase;Production;Prospective Studies;Proteins;R01 Mechanism;R01 Program;Rpg;Reproducibility;Research Grants;Research Personnel;Research Project Grants;Research Projects;Research Projects, R-Series;Researchers;Respiratory System, Lung;Reticuloendothelial System, Blood;Sarcoidosis;Schaumann's Disease;Sensitivity And Specificity;Serologic;Serological;Serum;Skin Part;Specificity;Symptoms;Techniques;Technology;Testing;Thorace;Thoracic;Thorax;Tuberculosis;Universities;University Medical Centers;Validation;Antibody;Bacterial Virus;Base;Biomarker;Body System, Allergic/Immunologic;Clinical Test;Combinatorial;Design;Designing;Disease /Disorder;Disease /Disorder Etiology;Disease Causation;Disease Etiology;Disease/Disorder;Disease/Disorder Etiology;Disorder Etiology;Disseminated Tb;Disseminated Tuberculosis;Environmental Agent;Gene Product;Host Response;Immunogen;Immunoreactivity;Immunoresponse;Infectious Organism;Library;Lymphogranulomatosis;Lymphogranulomatosis (Benign);New Diagnostics;New Technology;Next Generation Diagnostics;Novel Diagnostics;Organ System, Allergic/Immunologic;Polyclonal Antibody;Pulmonary;Research Clinical Testing;Response;Tuberculous Spondyloarthropathy;University
